BestPractice MEDtalk

– Utdannelse og faglig dialog

Fastleger

8:15

Atopic dermatitis – a clinical update

I en ny MEDtalk forteller Dr.Anita Remitz, overlege i dermatologi f…

<script src="https://fast.wistia.com/embed/medias/5i5la6jicu.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_5i5la6jicu videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/5i5la6jicu/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
10:52

Årskontroll av KOLS pasienter hos fastlegen

Er årskontroll av våre KOLS pasienter egentlig nødvendig og vikt…

<script src="https://fast.wistia.com/embed/medias/gz3wjkmhyd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_gz3wjkmhyd videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
10:42

Oppfølging av KOLS pasienter hos fastlegen

Oppfølging av KOLS pasienter i allmennpraksis er viktig;  hvordan…

<script src="https://fast.wistia.com/embed/medias/8f4kitg15j.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8f4kitg15j videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
17:45

GOLD Guidelines

GOLD-guidelines ved behandling av KOLS er nylig oppd…

<script src="https://fast.wistia.com/embed/medias/lg4ev92l31.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lg4ev92l31 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
11:27

Clinical proof points

Professor Matthias Born viser i denne MEDtalk den kliniske dokument…

<script src="https://fast.wistia.com/embed/medias/nhctpu0m5k.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_nhctpu0m5k videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
9:25

Lights and research

Gjennom denne korte BestPractice MEDtalks følger vi forsker og pro…

<script src="https://fast.wistia.com/embed/medias/tl4rqcikrq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_tl4rqcikrq videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:45

Philips Blue Light Control

Professor Matthias Born viser i denne MEDtalk devicet som er utvikl…

<script src="https://fast.wistia.com/embed/medias/0qpu1nlstc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_0qpu1nlstc videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
MEDtalk Plilips Blue Control med Matthias Born 6:11

Trends i light treatment

En ny type fototerapi er utviklet for plakkpsoriasis ved bruk av bl…

<script src="https://fast.wistia.com/embed/medias/79qq74gaeh.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_79qq74gaeh videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Tone Victoria Hjelset MEDtalk BestPractice 14:47

Positiv adferdsendring hos diabetespasienter

I denne MEDtalken forteller forsker ved seksjon for folkehelseviten…

<script src="https://fast.wistia.com/embed/medias/af8e2r3ojx.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_af8e2r3ojx videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
8:31

Urinsyreavleiringer

I denne MEDtalken med assisterende avdelingsoverlege Hilde Berner …

<script src="https://fast.wistia.com/embed/medias/np8d7nt1t4.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_np8d7nt1t4 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Till Ulig MEDtalk BestPrac 6:25

Kort om diagnostisering og behandling av urinsyregikt

I denne MEDtalken med professor Till Uhlig får du økt bevissthet …

<script src="https://fast.wistia.com/embed/medias/4mxi06u4ex.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4mxi06u4ex videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Kristian Furusteh BestPractice 18:57

Insuliner og kombinasjonsbehandling

I webinaret forteller fastlege Kristian Furuseth om insuliner og ko…

<script src="//fast.wistia.com/embed/medias/jib9eh5tc3.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jib9eh5tc3 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Trond Jenssen BestPractice utdannelse 15:40

Nyresykdom ved diabetes

I webinaret forteller professor Trond Jenssen om den siste oppdatering…

<script src="//fast.wistia.com/embed/medias/k0as3asvkw.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_k0as3asvkw videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Trond G. Jenssen BestPractice webinar 18:17

Blodsukkersenkende medikamentell behandling ved diabetes type 2

I webinaret forteller professor Trond Jenssen om den siste oppdatering…

<script src="//fast.wistia.com/embed/medias/di38ncne2z.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_di38ncne2z videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Trond G. Janssen webinar på BestPractice

Nytt om diabetes og kardiovaskulær risiko

Pasienter med diabetes har økt risiko for å dø av hjertekarsykdom. …

<script src="//fast.wistia.com/embed/medias/blnhgkdhla.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_blnhgkdhla videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Dermatologi

8:15

Atopic dermatitis – a clinical update

I en ny MEDtalk forteller Dr.Anita Remitz, overlege i dermatologi f…

<script src="https://fast.wistia.com/embed/medias/5i5la6jicu.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_5i5la6jicu videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/5i5la6jicu/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:51

EADV 2018: Vinner til en revolution for behandling av atopisk dermatitt

De senere år har gitt oss en forståelse av patogenesen for atopis…

<script src="https://fast.wistia.com/embed/medias/2vwpt03yo7.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_2vwpt03yo7 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/2vwpt03yo7/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:10

EADV 2018: Vi kan gjøre det enda bedre

Med den revolusjonerende behandling av psoriasis og atopisk dermati…

<script src="https://fast.wistia.com/embed/medias/jj92ly3nxe.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jj92ly3nxe videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/jj92ly3nxe/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:33

EADV 2018: Atopisk dermatitt i fokus på EADV

Kilian Eyerich, professor, Technical University of Munich, gir I de…

<script src="https://fast.wistia.com/embed/medias/l7oqnuew23.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_l7oqnuew23 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/l7oqnuew23/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:19

EADV 2018: Stigmatisering i dermatologien

Det er meget utbredt blant dermatologiske pasienter, at de opplever…

<script src="https://fast.wistia.com/embed/medias/0s3gniofpc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_0s3gniofpc videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/0s3gniofpc/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:10

EADV 2018: Onykoskopi oppdatering

Michela Starace, universitet i Bologna, gir en faglig oppdatering p…

<script src="https://fast.wistia.com/embed/medias/mzlosx5dev.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_mzlosx5dev videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/mzlosx5dev/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:04

EADV 2018: Behandlingsmålet for psoriasis endrer seg

Med de nye behandlingsmuligheter for psoriasis vil vi i de kommende…

<script src="https://fast.wistia.com/embed/medias/yzcxdor3zo.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yzcxdor3zo videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/yzcxdor3zo/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:39

EADV 2018: Møt EADV Board member Jørgen Serup

Gjennom mere enn 25 år har Jørgen Serup vært en del av EADV, og …

<script src="https://fast.wistia.com/embed/medias/26x8yol2ns.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_26x8yol2ns videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/26x8yol2ns/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:47

EADV 2018: EADV 2018 avspeiler en spesialitet i overføring

Jørgen Serup, overlege, professor ved Bispebjerg Hospital (DK) gir…

<script src="https://fast.wistia.com/embed/medias/obdpyjzatt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_obdpyjzatt videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/obdpyjzatt/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:59

EADV 2018: Nye aspekter ved immunterapi av maling melanom

Christian Blank, The Netherlands Cancer Institute, er en av nøkkel…

<script src="https://fast.wistia.com/embed/medias/ayhcwb34bj.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ayhcwb34bj videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/ayhcwb34bj/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>

EADV 2018: Dyp veiskille av psoriasis?

Rosa Parisi & Ireny Iskandar fra universitetet i Manchester (UK…

<script src="https://fast.wistia.com/embed/medias/1x6r362odr.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_1x6r362odr videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/1x6r362odr/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:12

EADV 2018: Store forventninger til bred pipeline

Få et innblikk i hvilke angrepspunkter og virkningsmekanismer, der…

<script src="https://fast.wistia.com/embed/medias/lil6jsl9h8.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lil6jsl9h8 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/lil6jsl9h8/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:06

EADV 2018: Nye behandlingsmuligheter ved psoriasis

BestPractice har bedt professor dr Marc Radtke, University Medical …

<script src="https://fast.wistia.com/embed/medias/tknfbdrlt8.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_tknfbdrlt8 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/tknfbdrlt8/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:13

EADV 2018: Nytt om IL-17 hemmer ved behandling av psoriasis

Proff. Dr. Marc Radtke, Universety Medical Center Hamburg- Eppendor…

<script src="https://fast.wistia.com/embed/medias/9dlgyl0qyh.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_9dlgyl0qyh videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/9dlgyl0qyh/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:16

EADV 2018: Interessant med langtidsdata for behandling av atopisk dermatitt

Med.Dr. MSc Laura B. von Kobyletzki, dermatologisk avdeling Malmø,…

<script src="https://fast.wistia.com/embed/medias/s6hzw57j82.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_s6hzw57j82 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/s6hzw57j82/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:17

EADV 2018: Fremtidens utfordring ved behandling av atopisk dermatitt

En lang rekke nye behandlingsmuligheter til atopisk dermatitt er p…

<script src="https://fast.wistia.com/embed/medias/9y94m82o1l.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_9y94m82o1l videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/9y94m82o1l/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:59

EADV 2018: Livskvalitet hos unge med akne skal bedres

Som dermatologer er vi interesserte i å hjelpe våre pasienter med…

<script src="https://fast.wistia.com/embed/medias/3mqag8l0ty.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3mqag8l0ty videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3mqag8l0ty/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:08

EADV 2018: Forventning om nye data og international networking

Åke Svensson, avdelingslege for Hudklinikken, Universitetssykehuse…

<script src="https://fast.wistia.com/embed/medias/6o0jrmv29x.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_6o0jrmv29x videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/6o0jrmv29x/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
11:27

Clinical proof points

Professor Matthias Born viser i denne MEDtalk den kliniske dokument…

<script src="https://fast.wistia.com/embed/medias/nhctpu0m5k.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_nhctpu0m5k videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
9:25

Lights and research

Gjennom denne korte BestPractice MEDtalks følger vi forsker og pro…

<script src="https://fast.wistia.com/embed/medias/tl4rqcikrq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_tl4rqcikrq videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:45

Philips Blue Light Control

Professor Matthias Born viser i denne MEDtalk devicet som er utvikl…

<script src="https://fast.wistia.com/embed/medias/0qpu1nlstc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_0qpu1nlstc videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
MEDtalk Plilips Blue Control med Matthias Born 6:11

Trends i light treatment

En ny type fototerapi er utviklet for plakkpsoriasis ved bruk av bl…

<script src="https://fast.wistia.com/embed/medias/79qq74gaeh.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_79qq74gaeh videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

EADV 2018

2:51

EADV 2018: Vinner til en revolution for behandling av atopisk dermatitt

De senere år har gitt oss en forståelse av patogenesen for atopis…

<script src="https://fast.wistia.com/embed/medias/2vwpt03yo7.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_2vwpt03yo7 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/2vwpt03yo7/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:10

EADV 2018: Vi kan gjøre det enda bedre

Med den revolusjonerende behandling av psoriasis og atopisk dermati…

<script src="https://fast.wistia.com/embed/medias/jj92ly3nxe.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jj92ly3nxe videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/jj92ly3nxe/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:33

EADV 2018: Atopisk dermatitt i fokus på EADV

Kilian Eyerich, professor, Technical University of Munich, gir I de…

<script src="https://fast.wistia.com/embed/medias/l7oqnuew23.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_l7oqnuew23 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/l7oqnuew23/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:19

EADV 2018: Stigmatisering i dermatologien

Det er meget utbredt blant dermatologiske pasienter, at de opplever…

<script src="https://fast.wistia.com/embed/medias/0s3gniofpc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_0s3gniofpc videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/0s3gniofpc/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:10

EADV 2018: Onykoskopi oppdatering

Michela Starace, universitet i Bologna, gir en faglig oppdatering p…

<script src="https://fast.wistia.com/embed/medias/mzlosx5dev.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_mzlosx5dev videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/mzlosx5dev/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:04

EADV 2018: Behandlingsmålet for psoriasis endrer seg

Med de nye behandlingsmuligheter for psoriasis vil vi i de kommende…

<script src="https://fast.wistia.com/embed/medias/yzcxdor3zo.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yzcxdor3zo videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/yzcxdor3zo/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:39

EADV 2018: Møt EADV Board member Jørgen Serup

Gjennom mere enn 25 år har Jørgen Serup vært en del av EADV, og …

<script src="https://fast.wistia.com/embed/medias/26x8yol2ns.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_26x8yol2ns videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/26x8yol2ns/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:47

EADV 2018: EADV 2018 avspeiler en spesialitet i overføring

Jørgen Serup, overlege, professor ved Bispebjerg Hospital (DK) gir…

<script src="https://fast.wistia.com/embed/medias/obdpyjzatt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_obdpyjzatt videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/obdpyjzatt/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:59

EADV 2018: Nye aspekter ved immunterapi av maling melanom

Christian Blank, The Netherlands Cancer Institute, er en av nøkkel…

<script src="https://fast.wistia.com/embed/medias/ayhcwb34bj.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ayhcwb34bj videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/ayhcwb34bj/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>

EADV 2018: Dyp veiskille av psoriasis?

Rosa Parisi & Ireny Iskandar fra universitetet i Manchester (UK…

<script src="https://fast.wistia.com/embed/medias/1x6r362odr.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_1x6r362odr videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/1x6r362odr/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:12

EADV 2018: Store forventninger til bred pipeline

Få et innblikk i hvilke angrepspunkter og virkningsmekanismer, der…

<script src="https://fast.wistia.com/embed/medias/lil6jsl9h8.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lil6jsl9h8 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/lil6jsl9h8/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:06

EADV 2018: Nye behandlingsmuligheter ved psoriasis

BestPractice har bedt professor dr Marc Radtke, University Medical …

<script src="https://fast.wistia.com/embed/medias/tknfbdrlt8.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_tknfbdrlt8 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/tknfbdrlt8/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:13

EADV 2018: Nytt om IL-17 hemmer ved behandling av psoriasis

Proff. Dr. Marc Radtke, Universety Medical Center Hamburg- Eppendor…

<script src="https://fast.wistia.com/embed/medias/9dlgyl0qyh.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_9dlgyl0qyh videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/9dlgyl0qyh/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:16

EADV 2018: Interessant med langtidsdata for behandling av atopisk dermatitt

Med.Dr. MSc Laura B. von Kobyletzki, dermatologisk avdeling Malmø,…

<script src="https://fast.wistia.com/embed/medias/s6hzw57j82.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_s6hzw57j82 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/s6hzw57j82/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:17

EADV 2018: Fremtidens utfordring ved behandling av atopisk dermatitt

En lang rekke nye behandlingsmuligheter til atopisk dermatitt er p…

<script src="https://fast.wistia.com/embed/medias/9y94m82o1l.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_9y94m82o1l videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/9y94m82o1l/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:59

EADV 2018: Livskvalitet hos unge med akne skal bedres

Som dermatologer er vi interesserte i å hjelpe våre pasienter med…

<script src="https://fast.wistia.com/embed/medias/3mqag8l0ty.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3mqag8l0ty videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3mqag8l0ty/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:08

EADV 2018: Forventning om nye data og international networking

Åke Svensson, avdelingslege for Hudklinikken, Universitetssykehuse…

<script src="https://fast.wistia.com/embed/medias/6o0jrmv29x.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_6o0jrmv29x videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/6o0jrmv29x/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>

Diabetes / Hjerte-Kar

11:39

Innvandrer og diabetes

Det er ingen grunn til at innvandrerbefolkningen med diabetes ikke …

<script src="https://fast.wistia.com/embed/medias/wzjkmx1fk1.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wzjkmx1fk1 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Tone Victoria Hjelset MEDtalk BestPractice 14:47

Kommunikasjon, mestring og motivasjon ved diabetes

I denne MEDtalk-en forteller forsker ved seksjon for folkehelsevite…

<script src="https://fast.wistia.com/embed/medias/af8e2r3ojx.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_af8e2r3ojx videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Kristian Furusteh BestPractice 18:57

Insuliner og kombinasjonsbehandling

I webinaret forteller fastlege Kristian Furuseth om insuliner og ko…

<script src="//fast.wistia.com/embed/medias/jib9eh5tc3.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jib9eh5tc3 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Trond Jenssen BestPractice utdannelse 15:40

Nyresykdom ved diabetes

I webinaret forteller professor Trond Jenssen om den siste oppdatering…

<script src="//fast.wistia.com/embed/medias/k0as3asvkw.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_k0as3asvkw videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Trond G. Jenssen BestPractice webinar 18:17

Blodsukkersenkende medikamentell behandling ved diabetes type 2

I webinaret forteller professor Trond Jenssen om den siste oppdatering…

<script src="//fast.wistia.com/embed/medias/di38ncne2z.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_di38ncne2z videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Trond G. Janssen webinar på BestPractice

Nytt om diabetes og kardiovaskulær risiko

Pasienter med diabetes har økt risiko for å dø av hjertekarsykdom. …

<script src="//fast.wistia.com/embed/medias/blnhgkdhla.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_blnhgkdhla videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Infeksjon/Vaksinasjon

9:48

LARs arbeide i Norge

Hør intervjuet med prosjektleder i LAR, Bent- Arild Stornes fortelle …

<script src="https://fast.wistia.com/embed/medias/v25da1mimm.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_v25da1mimm videoFoam=true" style="height:100%;position:relative;width:100%">&nbsp;</div></div></div>
15:38

Ekstrahepatiske Manifestasjoner av HCV infiserte

Hør foredraget til professor Olav Dalgard om Ekstrahepatiske Manifest…

<script src="https://fast.wistia.com/embed/medias/f758la3y08.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_f758la3y08 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
13:22

C-EDGE COSTAR resultatene

Hør foredraget til professor Olav Dalgard om C-EDGE COSTAR resultaten…

<script src="https://fast.wistia.com/embed/medias/hj64uaitbp.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_hj64uaitbp videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
INSHU 2016 Olov Dalgard 1:24

Forskning gjort på fibrosegrad hos rusmiddelbrukere

Hør hva professor Olav Dalgard fortelle fra sin poster på INHSU om f…

<script src="https://fast.wistia.com/embed/medias/v40h9mbpug.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_v40h9mbpug videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:18

Olov Dalgard forteller om INSHU

Hør hva Olav Dalgard som er president for INSHU fortelle om symposiet…

<script src="https://fast.wistia.com/embed/medias/ujfl28fkyh.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ujfl28fkyh videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Olov Dalgard på INSHU i Oslo 2016 2:35

Genotype 3 er den vanskeligste HCV formen å behandle

BestPractice besøkte INSHU symposiet og har gjort opptak og korte int…

<script src="https://fast.wistia.com/embed/medias/unli2ble1o.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_unli2ble1o videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Olov Dalgard fra INSHU 2016 2:29

Behandling med et nytt DAA tilgjengelig

BestPractice besøkte INSHU symposiet og har gjort opptak og korte int…

<script src="https://fast.wistia.com/embed/medias/hdklu43ip9.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_hdklu43ip9 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Bo Kielland INSHU 2016 15:42

HCV og fatigue hos pasienter som er smittet med hepatitt Knut Boe Kielland

BestPractice besøkte INSHU symposiet og har gjort opptak og korte int…

<script src="https://fast.wistia.com/embed/medias/ktgfv50oun.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ktgfv50oun videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Lungemedisin

17:45

GOLD Guidelines

GOLD-guidelines ved behandling av KOLS er nylig oppd…

<script src="https://fast.wistia.com/embed/medias/lg4ev92l31.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lg4ev92l31 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Onkologi /hematologi

2:16

Lavdosise interferon alpha vs. hydroxyurea i behandlingen av Ph-negative kroniske myeloproliferative neoplasier i dansk studie.

DALIAH-studien er en dansk investigator initiert randomisert fase III …

<script src="https://fast.wistia.com/embed/medias/4f2aq0kim5.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4f2aq0kim5 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4f2aq0kim5/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:65

PET og MDR negativitet som prognostisk markør ved follikulært lymfom

Professor Christiane Pott fremlegger nye data fra GALLIUM-studien som …

<script src="https://fast.wistia.com/embed/medias/17qmz0y6h6.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_17qmz0y6h6 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/17qmz0y6h6/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:40

Høy grad av klinisk respons ved førstelinje kombinasjonsbehandling av KLL.

Ved kombinasjon av ibrutinib og obinutuzumab som førstelinjebehandli…

<script src="https://fast.wistia.com/embed/medias/70vpn1li0t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_70vpn1li0t videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/70vpn1li0t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:12

Rutinemessig bruk av dyp sekventering ved KML

Resultatene fra den første prospektive studien av rutinemessig bruk a…

<script src="https://fast.wistia.com/embed/medias/di8h13na0l.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_di8h13na0l videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/di8h13na0l/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:16

Sikkerhetsdata for kombinasjonsbehandling av AL Amyoloidose

AL amyloidose er den hyppigste subgruppe ved amyoloidose. Avleiringene…

<script src="https://fast.wistia.com/embed/medias/57ux7vp3lq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_57ux7vp3lq videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/57ux7vp3lq/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:44

KML – de siste nyheter fra EHA 

Henrik Hjorth-Hansen, overlege, professor, St Olavs Hospital, har isæ…

<script src="https://fast.wistia.com/embed/medias/001wjvtrto.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_001wjvtrto videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/001wjvtrto/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:37

Signifikant økt PFS ved behandling av myelomatose

I fase III studien OPTIMISMM sammenlignet man 559 myelomatosepasienter…

<script src="https://fast.wistia.com/embed/medias/srdbhz8tm1.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_srdbhz8tm1 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/srdbhz8tm1/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:19

Flere interessante studier om myeloproliferative sykdommer

Overlege Eivind Galteland, Rikshospitalet i Oslo, tar flere interessan…

<script src="https://fast.wistia.com/embed/medias/wi2eo7wk9d.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wi2eo7wk9d videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/wi2eo7wk9d/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Nordisk studie viser at det er mulig å forbedre behandling av kronisk ITP

Waleed Ghanima, overlege ved Sykehuset Østfold, fremlegger i denne ME…

<script src="https://fast.wistia.com/embed/medias/lmzj98t078.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lmzj98t078 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/lmzj98t078/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:02

Trippelbehandling til høyrisikopasienter med myelomatose

Carfilzomib, cyclophosphamid and dexamethason er en effektiv og genere…

<script src="https://fast.wistia.com/embed/medias/abrvkav943.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abrvkav943 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abrvkav943/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Lovende resultater for diffus storcellet B-celle lymfom og follikulært lymfom

Polatuzumab vedotin er et konjugert antistoff som blokkerer CD79b+ cel…

<script src="https://fast.wistia.com/embed/medias/mb7jkiv0ds.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_mb7jkiv0ds videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/mb7jkiv0ds/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:35

Tidsbegrenset behandling av KLL-høyrisikopasienter med tilbakefall

Overlege Carsten Utoft Niemann, Hematologisk Avdeling, Rigshospitalet …

<script src="https://fast.wistia.com/embed/medias/osig3cjt4i.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_osig3cjt4i videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/osig3cjt4i/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:46

82% oppnår MDR-negativitet ved førstelinje KLL ved kombinasjonsbehandling

Ibrutinib og venetoclax brukt i kombinasjon hos naive KLL-pasienter fr…

<script src="https://fast.wistia.com/embed/medias/pkio9zi3uz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_pkio9zi3uz videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/pkio9zi3uz/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:17

Ynge mennesker med KLL vil kunne tilbys en ny effektiv kombinasjonsbehandling

Kombinasjonen  av duvelisib og FCR (fludarabin, cyclofosfamid, rituxi…

<script src="https://fast.wistia.com/embed/medias/xjtdj8poco.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xjtdj8poco videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xjtdj8poco/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Muligt at finde CLL-patienter med risiko for immundysfunktion

Der er en del CLL-patienter, der dør som følge af infektioner. Hvis …

<script src="https://fast.wistia.com/embed/medias/xmk0lmxggu.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xmk0lmxggu videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xmk0lmxggu/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:02

Bedre overlevelse for KLL-pasienter ved Gazyvaro behandling

KLL-pasienter med komorbiditet oppnår en bedre overlevelse med obinut…

<script src="https://fast.wistia.com/embed/medias/o9zw52ytrc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_o9zw52ytrc videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/o9zw52ytrc/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:15

Sekventering av behandling ved KLL

Selv om en lang rekke studier av behandling ved KLL nå pågår, så e…

<script src="https://fast.wistia.com/embed/medias/l3wn9ckeqd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_l3wn9ckeqd videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/l3wn9ckeqd/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:54

Bedre behandling av kuldeagglutininssykdom

Resultatene fra en nordisk studie fremlagt ved EHA i Stockholm viser a…

<script src="https://fast.wistia.com/embed/medias/h8i06fo6sd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_h8i06fo6sd videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/h8i06fo6sd/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
12:29

Discussion of established combinations and new combinations in multiple myeloma (2:3)

Watch dr. Fredrik Schjesvold take you through NEW documentation for…

<script src="https://fast.wistia.com/embed/medias/7giy7ui208.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_7giy7ui208 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/7giy7ui208/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:04

Vurdering av PSA-verdi og risiko for prostatakreft

Selvom ASCO ikke bød på de store gjennombrudd på prostatakreft-omr…

<script src="https://fast.wistia.com/embed/medias/y0p70e4v9u.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_y0p70e4v9u videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/y0p70e4v9u/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
12:06

Smouldering myeloma and high risk patients - a close look at GEM-CESAR and CENTAURUS studies (1:3)

Watch dr. Fredrik Schjesvold discuss smouldering myeloma and the tw…

<script src="https://fast.wistia.com/embed/medias/xypykci1kt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xypykci1kt videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xypykci1kt/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:58

Imponerende responsrate  ved B-celle lymfom

Behandling av…

<script src="https://fast.wistia.com/embed/medias/3xrkfabqpf.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3xrkfabqpf videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3xrkfabqpf/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
8:49

Should all eligible patients with multiple myeloma have tandem transplant? (3:3)

Watch dr. Fredrik Schjesvold take you through the documentation in …

<script src="https://fast.wistia.com/embed/medias/fqcwho4tnv.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fqcwho4tnv videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fqcwho4tnv/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:42

Bosutinib til pasienter med Ph+ leukemi

Carlo Gambacorti-Passerini, University of Milano-Bicocca, fremlegger…

<script src="https://fast.wistia.com/embed/medias/o6zokjrin9.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_o6zokjrin9 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/o6zokjrin9/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:22

Bedre overlevelse hos pasienter med EGFR-mutert lungekreft

Nye data utfordrer valg av behandling til pasienter med EGFR-mutert lu…

<script src="https://fast.wistia.com/embed/medias/e3dg6c7iiv.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_e3dg6c7iiv videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/e3dg6c7iiv/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:27

Sirkulerende biomarkør kan muligens forutsi effekt av behandlingen ved ovariekreft

Karina Dahl Steffensen, professor, overlæge ph.d., Onkologisk afdelin…

<script src="https://fast.wistia.com/embed/medias/fa0q1b9kv7.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fa0q1b9kv7 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fa0q1b9kv7/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:39

Oppsummering av lungekreftbehandling på ASCO 2018

Odd Terje Brustugun, leder av Norsk Lungekreft Gruppe og overlege, dr….

<script src="https://fast.wistia.com/embed/medias/cf1bsjyh1b.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_cf1bsjyh1b videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/cf1bsjyh1b/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:00

CAMELA studien gjør tverrfaglig vurdering obligatorisk ved metastatisk nyrekreft

Denne randomiserte, fase III og non-inferiority st…

<script src="https://fast.wistia.com/embed/medias/rfu4z4401n.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rfu4z4401n videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/rfu4z4401n/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:34

Flere nye interessant studier innen KLL og KML

Professor Bjørn Tore Gjertsen kommenterer på studier i KLL og KML, s…

<script src="https://fast.wistia.com/embed/medias/yo0hir56av.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yo0hir56av videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/yo0hir56av/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:56

Flytende biopsier, et svært lovende konsept innen onkologien

Flyende biopsier har stort potensiale innen diagnostikk, behandling og…

<script src="https://fast.wistia.com/embed/medias/ec5ty2m62l.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ec5ty2m62l videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/ec5ty2m62l/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:51

Oppsiktsvekkende resultater innen myelomatose

Hør denne MEDtalk om myelomatose og hva som er kommet av nyheter på …

<script src="https://fast.wistia.com/embed/medias/eghvlbohui.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_eghvlbohui videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/eghvlbohui/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:08

29% redusert risiko for sykdomsforverring eller død ved NSCLC

<script src="https://fast.wistia.com/embed/medias/fy73wl6404.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fy73wl6404 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fy73wl6404/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:00

Få pasienter hadde effekt av pembrolizumab ved ovarialcancer

<script src="https://fast.wistia.com/embed/medias/8qp17cmw40.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8qp17cmw40 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8qp17cmw40/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:05

Opsigtsvækkende resultater for Merkelcelle karcinom

En responsrate på 50% for patienter med kemoterapi-refratær Merkelce…

<script src="https://fast.wistia.com/embed/medias/75cpdgcrab.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_75cpdgcrab videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/75cpdgcrab/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:08

Målrettet behandling av prostatacancer i klinisk praksis

Oliver Sartor, professor, Medical Director, Tulane Cancer Center, gjø…

<script src="https://fast.wistia.com/embed/medias/0pzpqfox94.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_0pzpqfox94 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/0pzpqfox94/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:53

Optimering av adjuvant behandling ved HER2-positiv tidlig brystkreft

Der er i dag flere muligheter for individuell justering av  behandlin…

<script src="https://fast.wistia.com/embed/medias/3eb9jl2ntw.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3eb9jl2ntw videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3eb9jl2ntw/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:47

Vaksine bedrer progresjonsfri overlevelse betydelig ved ovarialcancer

Dendrittisk cellevaksine etterfulgt av cellegiftbehandling gir en bety…

<script src="https://fast.wistia.com/embed/medias/3fk3cd7zla.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3fk3cd7zla videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3fk3cd7zla/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:54

Immunterapi (avelumab) og ALK- inhibitoren loaratinib gir positive resultater i onkogen-drevet kreft

Denne kombinasjonen viste en re…

<script src="https://fast.wistia.com/embed/medias/fdh7n8l7d6.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fdh7n8l7d6 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fdh7n8l7d6/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:34

Immunterapi bør gis til pasienter med metastatisk melanom

Immunterapi med nivolumab eller pembroliz…

<script src="https://fast.wistia.com/embed/medias/husu7o4tc5.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_husu7o4tc5 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/husu7o4tc5/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:46

Positive resultater med avelumab til pasienter med metastatisk merkelcellekarsinom

Immunterapi til denne gruppen pasienter vil endre praksis forteller pr…

<script src="https://fast.wistia.com/embed/medias/8hnyhl8nzp.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8hnyhl8nzp videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8hnyhl8nzp/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:01

Livskvalitet og sikkerhetsresultater fra to NSCLC studier

Tidligere er positive overlevelsesdata for atezolizumab i lungekreft p…

<script src="https://fast.wistia.com/embed/medias/9k15ze0uvs.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_9k15ze0uvs videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/9k15ze0uvs/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:20

Blodprøve kan forutsi behandlingsrespons og prognose

NK-celle aktivitet er en tidlig prediktor for dårlig prognose og beha…

<script src="https://fast.wistia.com/embed/medias/n8s7pqkygr.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_n8s7pqkygr videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/n8s7pqkygr/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:49

Immunterapi med PD-1-hemmer ved platinumrefraktær eggstokkkreft med spredning

Dette retrospektive studie på 18 pasienter viser en sykdomskontroll p…

<script src="https://fast.wistia.com/embed/medias/gwzr09t3jj.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_gwzr09t3jj videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/gwzr09t3jj/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:20

Translasjonell forskning og nye biomarkører

Immunterapi har en liten plass i behandling av kolorektalcancer og kje…

<script src="https://fast.wistia.com/embed/medias/327qq34434.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_327qq34434 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/327qq34434/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:29

Venetoclax og ibrutinib som 1. linjebehandling ved KLL

Professor Catherine Diefenbach ved NYU Langone Medical Center og Perlm…

<script src="https://fast.wistia.com/embed/medias/33dc8213pg.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_33dc8213pg videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/33dc8213pg/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
5:15

Hør ASCO President Bruce Johnson fortelle om utviklingen av presisjonsmedisin og om immunterapi

Professor i Medicine ved Harvard Medical School, dr…

<script src="https://fast.wistia.com/embed/medias/qi5icv9l6b.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_qi5icv9l6b videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/qi5icv9l6b/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
0:59

MET-Amplified lungekreft

David Ross Camidge, MD, Director of Thoracic Oncology, University of C…

<script src="https://fast.wistia.com/embed/medias/ahfkx0db4k.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ahfkx0db4k videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/ahfkx0db4k/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:16

Neste generasjon ALK-inhibitor gir bedre overlevelse

ALK-inhibitoren alectinib er sammenlignet med crizotinib hos ubehandle…

<script src="https://fast.wistia.com/embed/medias/c5fzu68p0h.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_c5fzu68p0h videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/c5fzu68p0h/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:24

Immunterapien vil komme inn i flere tumorgrupper

En revolusjon startet i 2011 med immunterapi og den pågår enda.

<script src="https://fast.wistia.com/embed/medias/lnqt5j5fe4.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lnqt5j5fe4 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/lnqt5j5fe4/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:46

Kreftbehandling blir mer og mer persontilpasset

30.000 pasienter får kreft hvert år i Norge. Det er stort behov for …

<script src="https://fast.wistia.com/embed/medias/1lid0lq9ke.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_1lid0lq9ke videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/1lid0lq9ke/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:21

Norske onkologer bør delta på ASCO

Det er viktig for de små miljøene å bygge og utvikle nettverk med a…

<script src="https://fast.wistia.com/embed/medias/jgwi0prl43.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jgwi0prl43 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/jgwi0prl43/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:43

Hva med immunterapi i adjuvant setting?

Hør den interessante samtalen mellom leder i Norsk Onkologisk Forenin…

<script src="https://fast.wistia.com/embed/medias/1htnvaf13c.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_1htnvaf13c videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/1htnvaf13c/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:35

Progresjon med sjekkpunkt-inhibitor hos nyrekreftpasienter

Onkolog Mosche Ornstein fra Clinic Taussig Cancer Institute, Cleveland…

<script src="https://fast.wistia.com/embed/medias/8tnh6pzcgc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8tnh6pzcgc videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8tnh6pzcgc/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
5:31

Vurdering af prognosen for CLL-patienter med B-Celle receptor stereotypi

Nye data peger frem mod en mere individuel vurdering af den enkelte pa…

<script src="https://fast.wistia.com/embed/medias/yokdmu3ah0.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yokdmu3ah0 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
8:55

Minimal residual disease (MRD) and biomarker in CLL

What are the clinical role of MRD negativity and biomarkers in CLL….

<script src="https://fast.wistia.com/embed/medias/r1tmsjd75h.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_r1tmsjd75h videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
22:08

Frontline Therapy and Relapse Therapy of Advanced CLL

This MEDtalk with Dr. Barbara Eichorst, haematologist at the Univer…

<script src="https://fast.wistia.com/embed/medias/7x57qk3zvk.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_7x57qk3zvk videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:04

Risiko for dyp venetrombose og lungemboli ved cancer kan reduseres

Insidensen av venøs tromboemboli hos innlagte pasienter med aktiv …

<script src="https://fast.wistia.com/embed/medias/p3ldh8u144.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_p3ldh8u144 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:29

Større følsomhet for BCL2-hemmer ved KLL

Behandlingen av KLL er i en ny æra med flere nye behandlingsmulighet…

<script src="https://fast.wistia.com/embed/medias/s8fxeud5su.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_s8fxeud5su videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:08

Nivolumab-behandling ved Hodgkin lymfom

Patienter med relapse/refraktær klassisk Hodgkin lymfom behandlet med…

<script src="https://fast.wistia.com/embed/medias/xf8e3fcao0.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xf8e3fcao0 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:27

Imponerende data om KLL og KML

På flere sesjoner ble det presentert nye imponerende resultater fo…

<script src="https://fast.wistia.com/embed/medias/oo4elrwqq6.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_oo4elrwqq6 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:30

Nytt om kuldeagglutinin-syndrom og KML

Ny behandling av kuldeagglutinin-syndrom er nå en mulighet, ifølg…

<script src="https://fast.wistia.com/embed/medias/wekax8skrt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wekax8skrt videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:59

Paradigmeskift for bruk av MRD

Minimal residual disease, MRD, var fokus ved flere interessante ses…

<script src="https://fast.wistia.com/embed/medias/yzikdedzi7.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yzikdedzi7 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:48

Opphør av TKI-behandling ved KML

Varigheten av «Deep Molecular Response» er den viktigste faktoren…

<script src="https://fast.wistia.com/embed/medias/72t9odykyt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_72t9odykyt videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
10:13

Oppsiktsvekkende resultater

Pasienter med avansert Hodgkin lymfom i stadium III eller IV kan me…

<script src="https://fast.wistia.com/embed/medias/yk4ayqatqo.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yk4ayqatqo videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:10

Styring av behandlingsrespons

Valg av førstelinjebehandling ved myelomatose, styring av behandli…

<script src="https://fast.wistia.com/embed/medias/ii803fwnjq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ii803fwnjq videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:37
 

Ny førstelinjebehandling til yngre KLL-pasienter

I 2016 viste RESONATE-2 studien at Ibrutinib og Imbruvica kan bruke…

<script src="https://fast.wistia.com/embed/medias/letvgh7njw.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_letvgh7njw videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:44
 

TFR som nytt behandlingsmål for pasienter med KML-CP?

Evnen til å stoppe TKI-behandling uten å miste respons (dvs.: TFR…

<script src="https://fast.wistia.com/embed/medias/ivg1hzc94d.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ivg1hzc94d videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:57

Behov for ny kombinasjonsbehandling for mer varig remisjon

Til tross for den betydelige effekten med de nye legemidlene som ha…

<script src="https://fast.wistia.com/embed/medias/jkd9kojgzg.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jkd9kojgzg videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:18

Prediagnostisk progresjon av lymfocytose ved KLL

Kronisk lymfatisk leukemi (KLL) er en heterogen sykdom som utvikler…

<script src="https://fast.wistia.com/embed/medias/wf4qwsofjm.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wf4qwsofjm videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:44

Eldre KLL-pasienter får flest infeksjoner

En dansk registerstudie belyser forekomsten av infeksjoner hos pasi…

<script src="https://fast.wistia.com/embed/medias/rw60bopxdq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rw60bopxdq videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:06

MRD-negativitet har stor klinisk betydning

Flere nye data viser at oppnåelse av MRD-negativitet har stor klin…

<script src="https://fast.wistia.com/embed/medias/2xibfmyxtl.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_2xibfmyxtl videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:36

Ny standard for fremtidig behandling av myelomatose

Hør Jesús F. San-Miguel presentere noen av de mest betydningsfull…

<script src="https://fast.wistia.com/embed/medias/56nh79mh7b.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_56nh79mh7b videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:06

Stort fremskritt for behandling av myelomatose

Presentasjonen av langtidsdata for behandling av myelomatose med Da…

<script src="https://fast.wistia.com/embed/medias/ojyvgabolw.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ojyvgabolw videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
15:44

Håndtering av bivirkninger ved immunterapi

Forekomst…

<script src="https://fast.wistia.com/embed/medias/3v3vzfzirz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3v3vzfzirz videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:50

Hvordan vurderes effekt av immunterapi-behandlingen - radiologisk og klinisk

<script src="https://fast.wistia.com/embed/medias/49ijzhno1v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_49ijzhno1v videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
9:59

Biomarkører ved immunterapi

<script src="https://fast.wistia.com/embed/medias/rmcnle0xcb.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rmcnle0xcb videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Virkningsmekanismer ved immunterapi

<script src="https://fast.wistia.com/embed/medias/s77pzl2vjn.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_s77pzl2vjn videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
9:30

Status på opfølgning og behandling af follikulære lymfomer i Norge

I to moduler diskuterer Alexander Fosså og Bjørn Østedstad aktu…

<script src="https://fast.wistia.com/embed/medias/q10y6j69m3.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_q10y6j69m3 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
7:26

Status på behandling af Hodgins lymfom i Norge

I to moduler diskuterer Alexander Fosså og Bjørn Østedstad aktu…

<script src="https://fast.wistia.com/embed/medias/zmsbdq7wh7.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_zmsbdq7wh7 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
14:30

Behandling av follikulært lymfom

Bjørn Østenstad redegjør for behandling av follikulært lymfom o…

<script src="https://fast.wistia.com/embed/medias/zs2qcl3i0v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_zs2qcl3i0v videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
14:12

Behandling av Hodgins lymfom

I denne videoen redegjør Alexander Fossе for behandling av Hodgin…

<script src="https://fast.wistia.com/embed/medias/h3h2whi785.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_h3h2whi785 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Inge Marie Svane 10:32

Highlights fra ESMO om immunterapi

Totalt 45 sesjoner ved ESMO-konferansen handlet om immunterapi og er e…

<script src="https://fast.wistia.com/embed/medias/9g8hgsw4ab.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_9g8hgsw4ab videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:23

Paradigmeskifte på vei i behandling av lungekreft

Data fra PACIFIK-studien viser at immunterapi tredobler overlevelsen v…

<script src="https://fast.wistia.com/embed/medias/at9ka34qf8.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_at9ka34qf8 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:23

Abirateronacetat gir overlevelsesgevinst ved additiv behandling

Overlege og onkolog Jan Oldenburg, Akershus Universitetssykehus, forte…

<script src="https://fast.wistia.com/embed/medias/0u589i5gu4.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_0u589i5gu4 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:22

Melanompasienter får lengre DFS med adjuvant vemurafenib sammenlignet med placebo

Karl Lewis, associate professor of medicine, Division of Medical On…

<script src="https://fast.wistia.com/embed/medias/ts4c3gv8pz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ts4c3gv8pz videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:43

Behandling av høy risiko pasienter med melanom endres

På ESMO ble det fremlagt flere studier på melanom som vil endre beha…

<script src="https://fast.wistia.com/embed/medias/ysdwixpdvg.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ysdwixpdvg videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:05

Immunterapi gir bedre progresjonsfri overlevelse enn strålebehandling hos lungekreftpasienter

Overlege Åslaug Helland, OUS, gir her en kort status rapport på nye …

<script src="https://fast.wistia.com/embed/medias/tuib1udnh8.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_tuib1udnh8 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:43

T-celle terapi mot eggstokk-kreft

Magnus Pedersen, Center for cancer immunterapi, Herlev Hospital, freml…

<script src="https://fast.wistia.com/embed/medias/khgh87a9mq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_khgh87a9mq videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:37

Vaksine mot ikke-småcellet lungekreft i stadium III-IV

Kan vaksine bli en fremtidig behandling av lungekreft? Svaret på dett…

<script src="https://fast.wistia.com/embed/medias/vglzy3wjhd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_vglzy3wjhd videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
13:24

Sequencing therapy in multiple myeloma

Hør Philippe Moreau, Head of the Hematology Depar…

<script src="https://fast.wistia.com/embed/medias/52d5uq5kvv.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_52d5uq5kvv videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
11:55

How to treat patients in relapse following frontline ASCT

Best Practice har besøkt Philippe Moreau i Nantes og laget eksklus…

<script src="https://fast.wistia.com/embed/medias/j2on9wxcvw.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_j2on9wxcvw videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:24

Ny kandidat til 1. linjebehandling av EGFR-mutert ikke-småcellet lungekreft

Suresh S. Ramalingam, professor og director ved Winship Cancer Institu…

<script src="https://fast.wistia.com/embed/medias/e485ti378a.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_e485ti378a videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:59

Svikt av standard immunterapi ved malignt melanom

Pasienter med metastaserende malign melanom, som ikke responderer tils…

<script src="https://fast.wistia.com/embed/medias/c7d5xa37tt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_c7d5xa37tt videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:40

Viktig med faglig nettverk for sjeldne kreftsykdommer

Sjeldne cancersykdommer er ofte aggressive og rammer ofte yngre pasien…

<script src="https://fast.wistia.com/embed/medias/v5bdoflbl0.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_v5bdoflbl0 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:59

Pembrolizumab - ny standard som andrelinje behandling ved blærekreft

Behandling med Pembrolizumab tolereres godt, forlenger overlevelsen…

<script src="https://fast.wistia.com/embed/medias/c96u3exf58.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_c96u3exf58 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Fredrik Schjesvold Medtalk fra EHA 2017 Madrid 2:05

EHA - Behandlinger på vei til Norge på myelomatose

I videoen forteller overlege Fredrik Schjesvold, OUS, om de mange n…

<script src="https://fast.wistia.com/embed/medias/ws8v1xm9ct.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:55.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ws8v1xm9ct videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Fredrik Schjesvold Medtalk fra EHA 2017 3:46

Kort statusrapport på myelomatose fra årets EHA kongress i Madrid

Overlege Fredrik Schjesvold, OUS, gir en kort status på nye behand…

<script src="https://fast.wistia.com/embed/medias/w6srn5skki.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:55.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_w6srn5skki videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
ESMO 2016 42:34

Ny epoke i behandling av lungekreft

Der er med rette store forventninger til 2017. For det e…

<script src="//fast.wistia.com/embed/medias/b3mrtjpp0a.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b3mrtjpp0a videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
25:00

Eivind Galteland går gjennom behandlingsalternativer ved KLL

Overlege Eivind Galteland ved Rikshospitalet snakker behandling av …

<script src="//fast.wistia.com/embed/medias/8osse9u9d4.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8osse9u9d4 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Samtale mellem Eivind Galteland og Carsten Niemann 13:50

KLL BEHANDLING I 2017

Har du fått med deg oppdateringen på Kronisk Lymfatisk Leukemi? N…

<script src="//fast.wistia.com/embed/medias/62awlmxb7f.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_62awlmxb7f videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Carsten Niemann KLL MEDtalk BestPractice 23:37

Carsten Niemann, gir en oppdatering av de danske behandlingsanbefalinger ved KLL

Medlem av den danske guidelinekomitè Carsten Niemann ved Rigshospi…

<script src="//fast.wistia.com/embed/medias/fshz4mhvr8.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fshz4mhvr8 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:04

KLL intro

<script src="//fast.wistia.com/embed/medias/1vm3o1t5yy.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_1vm3o1t5yy videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
20:00

Nye guidelines Kronisk Lymfatisk Leukemi

Har du fått med deg oppdateringen på Kronisk Lymfatisk Leukemi? N…

<script src="//fast.wistia.com/embed/medias/1vm3o1t5yy.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_1vm3o1t5yy videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
BestPractice webinar med paneldiskusjon

Paneldiskusjonen om myelomatose

Paneldiskusjonen med hematologene Nina Gulbrandsen, Einar Haukås og A…

<script src="//fast.wistia.com/embed/medias/wyle1kb80w.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wyle1kb80w videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Philippe Moreau BestPractice webinar

Nye behandlingsmuligheter for pasienter med myelomatose

Gratis webinar med ekspertene Philippe Moureau og Anders Waage – panel…

<script src="//fast.wistia.com/embed/medias/u9a8zol34b.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_u9a8zol34b videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

ASCO 2018

3:04

Vurdering av PSA-verdi og risiko for prostatakreft

Selvom ASCO ikke bød på de store gjennombrudd på prostatakreft-omr…

<script src="https://fast.wistia.com/embed/medias/y0p70e4v9u.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_y0p70e4v9u videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/y0p70e4v9u/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:58

Imponerende responsrate  ved B-celle lymfom

Behandling av…

<script src="https://fast.wistia.com/embed/medias/3xrkfabqpf.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3xrkfabqpf videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3xrkfabqpf/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:42

Bosutinib til pasienter med Ph+ leukemi

Carlo Gambacorti-Passerini, University of Milano-Bicocca, fremlegger…

<script src="https://fast.wistia.com/embed/medias/o6zokjrin9.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_o6zokjrin9 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/o6zokjrin9/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:22

Bedre overlevelse hos pasienter med EGFR-mutert lungekreft

Nye data utfordrer valg av behandling til pasienter med EGFR-mutert lu…

<script src="https://fast.wistia.com/embed/medias/e3dg6c7iiv.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_e3dg6c7iiv videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/e3dg6c7iiv/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:27

Sirkulerende biomarkør kan muligens forutsi effekt av behandlingen ved ovariekreft

Karina Dahl Steffensen, professor, overlæge ph.d., Onkologisk afdelin…

<script src="https://fast.wistia.com/embed/medias/fa0q1b9kv7.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fa0q1b9kv7 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fa0q1b9kv7/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:39

Oppsummering av lungekreftbehandling på ASCO 2018

Odd Terje Brustugun, leder av Norsk Lungekreft Gruppe og overlege, dr….

<script src="https://fast.wistia.com/embed/medias/cf1bsjyh1b.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_cf1bsjyh1b videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/cf1bsjyh1b/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:00

CAMELA studien gjør tverrfaglig vurdering obligatorisk ved metastatisk nyrekreft

Denne randomiserte, fase III og non-inferiority st…

<script src="https://fast.wistia.com/embed/medias/rfu4z4401n.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rfu4z4401n videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/rfu4z4401n/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:34

Flere nye interessant studier innen KLL og KML

Professor Bjørn Tore Gjertsen kommenterer på studier i KLL og KML, s…

<script src="https://fast.wistia.com/embed/medias/yo0hir56av.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yo0hir56av videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/yo0hir56av/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:56

Flytende biopsier, et svært lovende konsept innen onkologien

Flyende biopsier har stort potensiale innen diagnostikk, behandling og…

<script src="https://fast.wistia.com/embed/medias/ec5ty2m62l.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ec5ty2m62l videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/ec5ty2m62l/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:51

Oppsiktsvekkende resultater innen myelomatose

Hør denne MEDtalk om myelomatose og hva som er kommet av nyheter på …

<script src="https://fast.wistia.com/embed/medias/eghvlbohui.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_eghvlbohui videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/eghvlbohui/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:08

29% redusert risiko for sykdomsforverring eller død ved NSCLC

<script src="https://fast.wistia.com/embed/medias/fy73wl6404.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fy73wl6404 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fy73wl6404/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:00

Få pasienter hadde effekt av pembrolizumab ved ovarialcancer

<script src="https://fast.wistia.com/embed/medias/8qp17cmw40.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8qp17cmw40 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8qp17cmw40/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:05

Opsigtsvækkende resultater for Merkelcelle karcinom

En responsrate på 50% for patienter med kemoterapi-refratær Merkelce…

<script src="https://fast.wistia.com/embed/medias/75cpdgcrab.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_75cpdgcrab videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/75cpdgcrab/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:08

Målrettet behandling av prostatacancer i klinisk praksis

Oliver Sartor, professor, Medical Director, Tulane Cancer Center, gjø…

<script src="https://fast.wistia.com/embed/medias/0pzpqfox94.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_0pzpqfox94 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/0pzpqfox94/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:53

Optimering av adjuvant behandling ved HER2-positiv tidlig brystkreft

Der er i dag flere muligheter for individuell justering av  behandlin…

<script src="https://fast.wistia.com/embed/medias/3eb9jl2ntw.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3eb9jl2ntw videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3eb9jl2ntw/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:47

Vaksine bedrer progresjonsfri overlevelse betydelig ved ovarialcancer

Dendrittisk cellevaksine etterfulgt av cellegiftbehandling gir en bety…

<script src="https://fast.wistia.com/embed/medias/3fk3cd7zla.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_3fk3cd7zla videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/3fk3cd7zla/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:54

Immunterapi (avelumab) og ALK- inhibitoren loaratinib gir positive resultater i onkogen-drevet kreft

Denne kombinasjonen viste en re…

<script src="https://fast.wistia.com/embed/medias/fdh7n8l7d6.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fdh7n8l7d6 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fdh7n8l7d6/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:34

Immunterapi bør gis til pasienter med metastatisk melanom

Immunterapi med nivolumab eller pembroliz…

<script src="https://fast.wistia.com/embed/medias/husu7o4tc5.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_husu7o4tc5 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/husu7o4tc5/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:46

Positive resultater med avelumab til pasienter med metastatisk merkelcellekarsinom

Immunterapi til denne gruppen pasienter vil endre praksis forteller pr…

<script src="https://fast.wistia.com/embed/medias/8hnyhl8nzp.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8hnyhl8nzp videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8hnyhl8nzp/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:01

Livskvalitet og sikkerhetsresultater fra to NSCLC studier

Tidligere er positive overlevelsesdata for atezolizumab i lungekreft p…

<script src="https://fast.wistia.com/embed/medias/9k15ze0uvs.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_9k15ze0uvs videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/9k15ze0uvs/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:20

Blodprøve kan forutsi behandlingsrespons og prognose

NK-celle aktivitet er en tidlig prediktor for dårlig prognose og beha…

<script src="https://fast.wistia.com/embed/medias/n8s7pqkygr.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_n8s7pqkygr videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/n8s7pqkygr/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:49

Immunterapi med PD-1-hemmer ved platinumrefraktær eggstokkkreft med spredning

Dette retrospektive studie på 18 pasienter viser en sykdomskontroll p…

<script src="https://fast.wistia.com/embed/medias/gwzr09t3jj.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_gwzr09t3jj videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/gwzr09t3jj/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:20

Translasjonell forskning og nye biomarkører

Immunterapi har en liten plass i behandling av kolorektalcancer og kje…

<script src="https://fast.wistia.com/embed/medias/327qq34434.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_327qq34434 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/327qq34434/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:29

Venetoclax og ibrutinib som 1. linjebehandling ved KLL

Professor Catherine Diefenbach ved NYU Langone Medical Center og Perlm…

<script src="https://fast.wistia.com/embed/medias/33dc8213pg.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_33dc8213pg videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/33dc8213pg/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
5:15

Hør ASCO President Bruce Johnson fortelle om utviklingen av presisjonsmedisin og om immunterapi

Professor i Medicine ved Harvard Medical School, dr…

<script src="https://fast.wistia.com/embed/medias/qi5icv9l6b.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_qi5icv9l6b videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/qi5icv9l6b/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
0:59

MET-Amplified lungekreft

David Ross Camidge, MD, Director of Thoracic Oncology, University of C…

<script src="https://fast.wistia.com/embed/medias/ahfkx0db4k.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ahfkx0db4k videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/ahfkx0db4k/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:16

Neste generasjon ALK-inhibitor gir bedre overlevelse

ALK-inhibitoren alectinib er sammenlignet med crizotinib hos ubehandle…

<script src="https://fast.wistia.com/embed/medias/c5fzu68p0h.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_c5fzu68p0h videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/c5fzu68p0h/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:24

Immunterapien vil komme inn i flere tumorgrupper

En revolusjon startet i 2011 med immunterapi og den pågår enda.

<script src="https://fast.wistia.com/embed/medias/lnqt5j5fe4.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lnqt5j5fe4 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/lnqt5j5fe4/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:46

Kreftbehandling blir mer og mer persontilpasset

30.000 pasienter får kreft hvert år i Norge. Det er stort behov for …

<script src="https://fast.wistia.com/embed/medias/1lid0lq9ke.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_1lid0lq9ke videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/1lid0lq9ke/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:21

Norske onkologer bør delta på ASCO

Det er viktig for de små miljøene å bygge og utvikle nettverk med a…

<script src="https://fast.wistia.com/embed/medias/jgwi0prl43.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jgwi0prl43 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/jgwi0prl43/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:43

Hva med immunterapi i adjuvant setting?

Hør den interessante samtalen mellom leder i Norsk Onkologisk Forenin…

<script src="https://fast.wistia.com/embed/medias/1htnvaf13c.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_1htnvaf13c videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/1htnvaf13c/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:35

Progresjon med sjekkpunkt-inhibitor hos nyrekreftpasienter

Onkolog Mosche Ornstein fra Clinic Taussig Cancer Institute, Cleveland…

<script src="https://fast.wistia.com/embed/medias/8tnh6pzcgc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_8tnh6pzcgc videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/8tnh6pzcgc/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>

ASH 2017

12:29

Discussion of established combinations and new combinations in multiple myeloma (2:3)

Watch dr. Fredrik Schjesvold take you through NEW documentation for…

<script src="https://fast.wistia.com/embed/medias/7giy7ui208.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_7giy7ui208 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/7giy7ui208/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
12:06

Smouldering myeloma and high risk patients - a close look at GEM-CESAR and CENTAURUS studies (1:3)

Watch dr. Fredrik Schjesvold discuss smouldering myeloma and the tw…

<script src="https://fast.wistia.com/embed/medias/xypykci1kt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xypykci1kt videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xypykci1kt/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
8:49

Should all eligible patients with multiple myeloma have tandem transplant? (3:3)

Watch dr. Fredrik Schjesvold take you through the documentation in …

<script src="https://fast.wistia.com/embed/medias/fqcwho4tnv.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_fqcwho4tnv videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/fqcwho4tnv/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
5:31

Vurdering af prognosen for CLL-patienter med B-Celle receptor stereotypi

Nye data peger frem mod en mere individuel vurdering af den enkelte pa…

<script src="https://fast.wistia.com/embed/medias/yokdmu3ah0.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yokdmu3ah0 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:04

Risiko for dyp venetrombose og lungemboli ved cancer kan reduseres

Insidensen av venøs tromboemboli hos innlagte pasienter med aktiv …

<script src="https://fast.wistia.com/embed/medias/p3ldh8u144.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_p3ldh8u144 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:29

Større følsomhet for BCL2-hemmer ved KLL

Behandlingen av KLL er i en ny æra med flere nye behandlingsmulighet…

<script src="https://fast.wistia.com/embed/medias/s8fxeud5su.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_s8fxeud5su videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:08

Nivolumab-behandling ved Hodgkin lymfom

Patienter med relapse/refraktær klassisk Hodgkin lymfom behandlet med…

<script src="https://fast.wistia.com/embed/medias/xf8e3fcao0.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xf8e3fcao0 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:27

Imponerende data om KLL og KML

På flere sesjoner ble det presentert nye imponerende resultater fo…

<script src="https://fast.wistia.com/embed/medias/oo4elrwqq6.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_oo4elrwqq6 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:30

Nytt om kuldeagglutinin-syndrom og KML

Ny behandling av kuldeagglutinin-syndrom er nå en mulighet, ifølg…

<script src="https://fast.wistia.com/embed/medias/wekax8skrt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wekax8skrt videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:59

Paradigmeskift for bruk av MRD

Minimal residual disease, MRD, var fokus ved flere interessante ses…

<script src="https://fast.wistia.com/embed/medias/yzikdedzi7.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yzikdedzi7 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:48

Opphør av TKI-behandling ved KML

Varigheten av «Deep Molecular Response» er den viktigste faktoren…

<script src="https://fast.wistia.com/embed/medias/72t9odykyt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_72t9odykyt videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
10:13

Oppsiktsvekkende resultater

Pasienter med avansert Hodgkin lymfom i stadium III eller IV kan me…

<script src="https://fast.wistia.com/embed/medias/yk4ayqatqo.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_yk4ayqatqo videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:10

Styring av behandlingsrespons

Valg av førstelinjebehandling ved myelomatose, styring av behandli…

<script src="https://fast.wistia.com/embed/medias/ii803fwnjq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ii803fwnjq videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:37
 

Ny førstelinjebehandling til yngre KLL-pasienter

I 2016 viste RESONATE-2 studien at Ibrutinib og Imbruvica kan bruke…

<script src="https://fast.wistia.com/embed/medias/letvgh7njw.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_letvgh7njw videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:44
 

TFR som nytt behandlingsmål for pasienter med KML-CP?

Evnen til å stoppe TKI-behandling uten å miste respons (dvs.: TFR…

<script src="https://fast.wistia.com/embed/medias/ivg1hzc94d.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ivg1hzc94d videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:57

Behov for ny kombinasjonsbehandling for mer varig remisjon

Til tross for den betydelige effekten med de nye legemidlene som ha…

<script src="https://fast.wistia.com/embed/medias/jkd9kojgzg.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jkd9kojgzg videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:18

Prediagnostisk progresjon av lymfocytose ved KLL

Kronisk lymfatisk leukemi (KLL) er en heterogen sykdom som utvikler…

<script src="https://fast.wistia.com/embed/medias/wf4qwsofjm.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wf4qwsofjm videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:44

Eldre KLL-pasienter får flest infeksjoner

En dansk registerstudie belyser forekomsten av infeksjoner hos pasi…

<script src="https://fast.wistia.com/embed/medias/rw60bopxdq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rw60bopxdq videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:06

MRD-negativitet har stor klinisk betydning

Flere nye data viser at oppnåelse av MRD-negativitet har stor klin…

<script src="https://fast.wistia.com/embed/medias/2xibfmyxtl.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_2xibfmyxtl videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:36

Ny standard for fremtidig behandling av myelomatose

Hør Jesús F. San-Miguel presentere noen av de mest betydningsfull…

<script src="https://fast.wistia.com/embed/medias/56nh79mh7b.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_56nh79mh7b videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
4:06

Stort fremskritt for behandling av myelomatose

Presentasjonen av langtidsdata for behandling av myelomatose med Da…

<script src="https://fast.wistia.com/embed/medias/ojyvgabolw.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ojyvgabolw videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

EHA 2018

2:16

Lavdosise interferon alpha vs. hydroxyurea i behandlingen av Ph-negative kroniske myeloproliferative neoplasier i dansk studie.

DALIAH-studien er en dansk investigator initiert randomisert fase III …

<script src="https://fast.wistia.com/embed/medias/4f2aq0kim5.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4f2aq0kim5 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4f2aq0kim5/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:65

PET og MDR negativitet som prognostisk markør ved follikulært lymfom

Professor Christiane Pott fremlegger nye data fra GALLIUM-studien som …

<script src="https://fast.wistia.com/embed/medias/17qmz0y6h6.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_17qmz0y6h6 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/17qmz0y6h6/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:40

Høy grad av klinisk respons ved førstelinje kombinasjonsbehandling av KLL.

Ved kombinasjon av ibrutinib og obinutuzumab som førstelinjebehandli…

<script src="https://fast.wistia.com/embed/medias/70vpn1li0t.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_70vpn1li0t videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/70vpn1li0t/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:12

Rutinemessig bruk av dyp sekventering ved KML

Resultatene fra den første prospektive studien av rutinemessig bruk a…

<script src="https://fast.wistia.com/embed/medias/di8h13na0l.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_di8h13na0l videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/di8h13na0l/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:16

Sikkerhetsdata for kombinasjonsbehandling av AL Amyoloidose

AL amyloidose er den hyppigste subgruppe ved amyoloidose. Avleiringene…

<script src="https://fast.wistia.com/embed/medias/57ux7vp3lq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_57ux7vp3lq videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/57ux7vp3lq/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
1:44

KML – de siste nyheter fra EHA 

Henrik Hjorth-Hansen, overlege, professor, St Olavs Hospital, har isæ…

<script src="https://fast.wistia.com/embed/medias/001wjvtrto.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_001wjvtrto videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/001wjvtrto/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:37

Signifikant økt PFS ved behandling av myelomatose

I fase III studien OPTIMISMM sammenlignet man 559 myelomatosepasienter…

<script src="https://fast.wistia.com/embed/medias/srdbhz8tm1.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_srdbhz8tm1 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/srdbhz8tm1/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:19

Flere interessante studier om myeloproliferative sykdommer

Overlege Eivind Galteland, Rikshospitalet i Oslo, tar flere interessan…

<script src="https://fast.wistia.com/embed/medias/wi2eo7wk9d.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_wi2eo7wk9d videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/wi2eo7wk9d/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Nordisk studie viser at det er mulig å forbedre behandling av kronisk ITP

Waleed Ghanima, overlege ved Sykehuset Østfold, fremlegger i denne ME…

<script src="https://fast.wistia.com/embed/medias/lmzj98t078.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_lmzj98t078 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/lmzj98t078/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
6:02

Trippelbehandling til høyrisikopasienter med myelomatose

Carfilzomib, cyclophosphamid and dexamethason er en effektiv og genere…

<script src="https://fast.wistia.com/embed/medias/abrvkav943.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abrvkav943 videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abrvkav943/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Lovende resultater for diffus storcellet B-celle lymfom og follikulært lymfom

Polatuzumab vedotin er et konjugert antistoff som blokkerer CD79b+ cel…

<script src="https://fast.wistia.com/embed/medias/mb7jkiv0ds.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_mb7jkiv0ds videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/mb7jkiv0ds/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:35

Tidsbegrenset behandling av KLL-høyrisikopasienter med tilbakefall

Overlege Carsten Utoft Niemann, Hematologisk Avdeling, Rigshospitalet …

<script src="https://fast.wistia.com/embed/medias/osig3cjt4i.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_osig3cjt4i videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/osig3cjt4i/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:46

82% oppnår MDR-negativitet ved førstelinje KLL ved kombinasjonsbehandling

Ibrutinib og venetoclax brukt i kombinasjon hos naive KLL-pasienter fr…

<script src="https://fast.wistia.com/embed/medias/pkio9zi3uz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_pkio9zi3uz videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/pkio9zi3uz/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:17

Ynge mennesker med KLL vil kunne tilbys en ny effektiv kombinasjonsbehandling

Kombinasjonen  av duvelisib og FCR (fludarabin, cyclofosfamid, rituxi…

<script src="https://fast.wistia.com/embed/medias/xjtdj8poco.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xjtdj8poco videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xjtdj8poco/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
2:58

Muligt at finde CLL-patienter med risiko for immundysfunktion

Der er en del CLL-patienter, der dør som følge af infektioner. Hvis …

<script src="https://fast.wistia.com/embed/medias/xmk0lmxggu.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_xmk0lmxggu videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/xmk0lmxggu/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:02

Bedre overlevelse for KLL-pasienter ved Gazyvaro behandling

KLL-pasienter med komorbiditet oppnår en bedre overlevelse med obinut…

<script src="https://fast.wistia.com/embed/medias/o9zw52ytrc.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_o9zw52ytrc videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/o9zw52ytrc/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
3:15

Sekventering av behandling ved KLL

Selv om en lang rekke studier av behandling ved KLL nå pågår, så e…

<script src="https://fast.wistia.com/embed/medias/l3wn9ckeqd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_l3wn9ckeqd videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/l3wn9ckeqd/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
4:54

Bedre behandling av kuldeagglutininssykdom

Resultatene fra en nordisk studie fremlagt ved EHA i Stockholm viser a…

<script src="https://fast.wistia.com/embed/medias/h8i06fo6sd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_h8i06fo6sd videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/h8i06fo6sd/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>

ESMO 2017

Inge Marie Svane 10:32

Highlights fra ESMO om immunterapi

Totalt 45 sesjoner ved ESMO-konferansen handlet om immunterapi og er e…

<script src="https://fast.wistia.com/embed/medias/9g8hgsw4ab.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_9g8hgsw4ab videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:23

Paradigmeskifte på vei i behandling av lungekreft

Data fra PACIFIK-studien viser at immunterapi tredobler overlevelsen v…

<script src="https://fast.wistia.com/embed/medias/at9ka34qf8.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_at9ka34qf8 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:23

Abirateronacetat gir overlevelsesgevinst ved additiv behandling

Overlege og onkolog Jan Oldenburg, Akershus Universitetssykehus, forte…

<script src="https://fast.wistia.com/embed/medias/0u589i5gu4.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_0u589i5gu4 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:22

Melanompasienter får lengre DFS med adjuvant vemurafenib sammenlignet med placebo

Karl Lewis, associate professor of medicine, Division of Medical On…

<script src="https://fast.wistia.com/embed/medias/ts4c3gv8pz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ts4c3gv8pz videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:43

Behandling av høy risiko pasienter med melanom endres

På ESMO ble det fremlagt flere studier på melanom som vil endre beha…

<script src="https://fast.wistia.com/embed/medias/ysdwixpdvg.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_ysdwixpdvg videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:05

Immunterapi gir bedre progresjonsfri overlevelse enn strålebehandling hos lungekreftpasienter

Overlege Åslaug Helland, OUS, gir her en kort status rapport på nye …

<script src="https://fast.wistia.com/embed/medias/tuib1udnh8.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_tuib1udnh8 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:43

T-celle terapi mot eggstokk-kreft

Magnus Pedersen, Center for cancer immunterapi, Herlev Hospital, freml…

<script src="https://fast.wistia.com/embed/medias/khgh87a9mq.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_khgh87a9mq videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
3:37

Vaksine mot ikke-småcellet lungekreft i stadium III-IV

Kan vaksine bli en fremtidig behandling av lungekreft? Svaret på dett…

<script src="https://fast.wistia.com/embed/medias/vglzy3wjhd.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_vglzy3wjhd videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:24

Ny kandidat til 1. linjebehandling av EGFR-mutert ikke-småcellet lungekreft

Suresh S. Ramalingam, professor og director ved Winship Cancer Institu…

<script src="https://fast.wistia.com/embed/medias/e485ti378a.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_e485ti378a videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:59

Svikt av standard immunterapi ved malignt melanom

Pasienter med metastaserende malign melanom, som ikke responderer tils…

<script src="https://fast.wistia.com/embed/medias/c7d5xa37tt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_c7d5xa37tt videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
2:40

Viktig med faglig nettverk for sjeldne kreftsykdommer

Sjeldne cancersykdommer er ofte aggressive og rammer ofte yngre pasien…

<script src="https://fast.wistia.com/embed/medias/v5bdoflbl0.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_v5bdoflbl0 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
1:59

Pembrolizumab - ny standard som andrelinje behandling ved blærekreft

Behandling med Pembrolizumab tolereres godt, forlenger overlevelsen…

<script src="https://fast.wistia.com/embed/medias/c96u3exf58.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_c96u3exf58 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

ESMO2016NO

ESMO 2016 42:34

Ny epoke i behandling av lungekreft

Der er med rette store forventninger til 2017. For det e…

<script src="//fast.wistia.com/embed/medias/b3mrtjpp0a.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_b3mrtjpp0a videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Psykiatri / Neurologi

13:02

Resetting av immunsystemet ved multippel sklerose

Behandlingstrategien ved multippel sklerose har endret seg de sener…

<script src="https://fast.wistia.com/embed/medias/dd0be4c16g.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_dd0be4c16g videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Multipel sklerose

13:02

Resetting av immunsystemet ved multippel sklerose

Behandlingstrategien ved multippel sklerose har endret seg de sener…

<script src="https://fast.wistia.com/embed/medias/dd0be4c16g.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_dd0be4c16g videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Revmatologi

20:08

Behandling av RA med JAK-hemmere - Australske kliniske erfaringer

Ifølge de oppdaterte EULAR guidelines er JAK-hemmere nå et likeve…

<script src="https://fast.wistia.com/embed/medias/tjwnumw3wt.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_tjwnumw3wt videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
21:07

The importance of early diagnosis and new treatment of RA

This Medtalk is a conversation among former EULAR president and Pro…

<script src="https://fast.wistia.com/embed/medias/6mogui3vcv.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_6mogui3vcv videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Tore Kvien MEDtalk BestPractice 4:46

NOR-SWITCH-studien publisert i The Lancet

En norsk studie viser at det er trygt å bytte fra kostbar original…

<script src="https://fast.wistia.com/embed/medias/tq90mtjz2s.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.0% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_tq90mtjz2s videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Tore Kvien MEDtalk BestPractice 12:58

Ny tablettbehandling godkjent til revmatoid artritt (RA)

I denne MEDtalken redegjør Tore Kristian Kvien, professor og avdel…

<script src="https://fast.wistia.com/embed/medias/zu64sdqb6c.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_zu64sdqb6c videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>
Tore Kvien MEDtalk BestPractice 4:42

Nye anbefalinger om revmatisk sykdom og hjertesykdom

Få med deg de siste anbefalinger av revmatolog og professor Tore K. K…

<script src="//fast.wistia.com/embed/medias/hloo8b7dd7.jsonp" async></script><script src="//fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_hloo8b7dd7 videoFoam=true" style="height:100%;width:100%">&nbsp;</div></div></div>

Kommende WebinarKommende Webinar

November 28, 2018 12:05

Siste innen behandling av alvorlig astma

Professor Andrew Menzies-Gow I Lungemedisin

TILMELD DIG HER